SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Express Scripts to add Zepbound to National Preferred Formulary
In clinical trials, treatment proved more effective than other therapies evaluated
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Subscribe To Our Newsletter & Stay Updated
